Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Fellermann

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Digestive Diseases (Basel, Switzerland)|November 20, 2013
Adverse events of tumor necrosis factor inhibitorsKlaus Fellermann
World Journal of Gastroenterology|April 5, 2013
Thiopurines in inflammatory bowel disease revisitedFlorian Bär, Christian Sina, Klaus Fellermann
Chemical Immunology and Allergy|June 25, 2005
Human defensins in Crohn's diseaseJan Wehkamp, Klaus Fellermann, Eduard F Stange
Expert Opinion on Biological Therapy|January 24, 2014
Therapeutic peptides in inflammatory bowel diseaseKlaus R Herrlinger, Eduard F Stange, Klaus Fellermann
Gut|April 26, 2007
Reduced mucosal antimicrobial activity in Crohn's disease of the colonSabine Nuding, Klaus Fellermann, Jan Wehkamp, et al.
Journal of Leukocyte Biology|December 25, 2004
Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's diseaseJan Wehkamp, Michael Schmid, Klaus Fellermann, et al.
World Journal of Gastroenterology|September 24, 2008
Crohn's disease--defect in innate defenceMichael Gersemann, Jan Wehkamp, Klaus Fellermann, et al.
European Journal of Gastroenterology & Hepatology|July 4, 2003
Crohn's disease: a defensin deficiency syndrome?Klaus Fellermann, Jan Wehkamp, Klaus R Herrlinger, et al.
Current Drug Discovery Technologies|December 23, 2009
Crohn's targeted therapy: myth or real goal?Klaus J Schmidt, Jürgen Büning, Carsten Jankowiak, et al.
Journal of Crohn'S & Colitis|November 26, 2011
Cyclophosphamide therapy in Sweet's syndrome complicating refractory Crohn's disease − Efficacy and mechanism of actionChristian Meinhardt, Jürgen Büning, Klaus Fellermann, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Digestive Diseases (Basel, Switzerland)|November 20, 2013
Adverse events of tumor necrosis factor inhibitorsKlaus Fellermann
World Journal of Gastroenterology|April 5, 2013
Thiopurines in inflammatory bowel disease revisitedFlorian Bär, Christian Sina, Klaus Fellermann
Chemical Immunology and Allergy|June 25, 2005
Human defensins in Crohn's diseaseJan Wehkamp, Klaus Fellermann, Eduard F Stange
Expert Opinion on Biological Therapy|January 24, 2014
Therapeutic peptides in inflammatory bowel diseaseKlaus R Herrlinger, Eduard F Stange, Klaus Fellermann
Gut|April 26, 2007
Reduced mucosal antimicrobial activity in Crohn's disease of the colonSabine Nuding, Klaus Fellermann, Jan Wehkamp, et al.
Journal of Leukocyte Biology|December 25, 2004
Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's diseaseJan Wehkamp, Michael Schmid, Klaus Fellermann, et al.
World Journal of Gastroenterology|September 24, 2008
Crohn's disease--defect in innate defenceMichael Gersemann, Jan Wehkamp, Klaus Fellermann, et al.
European Journal of Gastroenterology & Hepatology|July 4, 2003
Crohn's disease: a defensin deficiency syndrome?Klaus Fellermann, Jan Wehkamp, Klaus R Herrlinger, et al.
Current Drug Discovery Technologies|December 23, 2009
Crohn's targeted therapy: myth or real goal?Klaus J Schmidt, Jürgen Büning, Carsten Jankowiak, et al.
Journal of Crohn'S & Colitis|November 26, 2011
Cyclophosphamide therapy in Sweet's syndrome complicating refractory Crohn's disease − Efficacy and mechanism of actionChristian Meinhardt, Jürgen Büning, Klaus Fellermann, et al.
Pageof 6